An assessment of the functions of Pfizer, the Serum Institute of India, and of Bharath Biotech for their Covid-19 vaccine candidates, as official reports suggested on Monday night, are scheduled to meet the expert committee of the Central Drugs Quality Control Organisation (CDS COM).
The decision was made late in the evening, following the development of Bharat Biotech, the Hyderabad-based firm, to be the third drug agency for the emergency use of the Covaxin vaccine, the DCGI (Drugs Controller General of India).
On December 4, the Indian arm of US pharmaceuticals big Pfizer had requested permission from the Central Medicine Regulator for its vaccine, after that clearance had been obtained by the agency in the UK and Bahrain.
The Oxford Covid-19 vaccine in covishield was pursued on 6 December by the Pune-based Serum Institute of India.
“DCGI has already begun application processing. On 9 December, on the application for emergency use authorization of its COVID-19 vaccinations, the Topic Expert Committee (SEC) at CDSCO will address requests from Pfizer, Serum Institute of India, and Bharat Biotech, a supply that is indicated.
Following the review of the supply, SEC will provide the DCGI with its recommendations about whether or not a validation of the emergency use could be given for vaccine candidates.
Prime Minister Narendra Modi expressed optimism at a full-party meeting on December 4 that a vaccine against Covid-19 could also be planned in a couple of weeks’ time.